This is a transformative catalyst for HUTCHMED — the SAFFRON data provide the global registration package for the ORPATHYS + TAGRISSO combination, which could expand the addressable market beyond China. Traders should watch for regulatory submission timelines (FDA, EMA) and potential partnership milestones from AstraZeneca. The stock may gap up significantly on this news given the high unmet need and biomarker-directed nature of the therapy.
Price Chart
Executive Summary
HUTCHMED announced positive Phase III SAFFRON trial results showing savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) significantly improved progression-free survival and overall survival vs chemotherapy in EGFR-mutant NSCLC patients with MET-driven resistance after TAGRISSO progression. This is a high-impact catalyst for global registration of the combination, addressing a large unmet need in a biomarker-defined population with no prior oral targeted option.
Key Facts
- SAFFRON Phase III met primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness
- Trial enrolled 338 patients across 29 countries in 230 centers
- Combination addresses MET overexpression/amplification, which occurs in ~34% of patients after third-generation EGFR TKI progression
- ORPATHYS plus TAGRISSO already approved in China based on SACHI Phase III; SAFFRON supports global registrations
- Safety profile consistent with known profiles of each medicine; no new safety findings
- Data to be presented at forthcoming medical meeting and shared with global regulatory authorities
Financial Impact
Positive readout for a global Phase III trial in a large addressable NSCLC population with MET-driven resistance; potential to unlock multi-billion-dollar peak sales for the combination globally
Risk Factors
- Regulatory timelines and approval decisions are uncertain; FDA/EMA may require additional data
- Competition from other MET-targeted agents in development
- Commercial uptake depends on biomarker testing adoption (MET IHC/FISH) in clinical practice
- HUTCHMED CEO currently on leave of absence, which may create operational uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345800 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access